Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Marvell Technology Inc (MRVL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hinge Health Inc. Class A Common Stock vs Marvell Technology Inc — how do they compare? Hinge Health Inc. Class A Common Stock trades at $103.99 (market cap $8.47B), while Marvell Technology Inc trades at $238.41 (market cap $220.43B). The key difference: Marvell Technology Inc is far larger — about 26× Hinge Health Inc. Class A Common Stock's market cap, and Marvell Technology Inc pays a 0.1% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Marvell Technology Inc for 43 Days on average.
| HNGE | MRVL | |
|---|---|---|
Market Cap | $8.47B | $220.43B |
Volume | 1,624,526 | 25,874,039 |
Sector | Health | Technology |
52-Week High | $105.14 | $316.43 |
52-Week Low | $31.17 | $73.73 |
Typical Hold Time | 0 Days | 43 Days |
Enterprise Value | $8.09B | $221.79B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Marvell Technology (MRVL) trades at $268.73, up 1.08% today, with a bullish technical signal from moving averages and strong analyst support. The company reported three consecutive quarterly EPS beats and projects robust revenue growth, driven by AI and data center demand. Recent news highlights a $120 billion potential deal with Google and raised fiscal 2028 guidance to $18 billion, fueling investor optimism despite high valuation multiples.
Outlook remains positive with a consensus price target of $327.86, implying 22% upside, but risks include elevated P/E of 88.98 and dependence on hyperscaler contracts. Net losses in 2025 contrast with projected 2026 profitability, requiring execution on custom chip growth to justify valuations amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →
